ACR encouraged by imagings contribution to cancer death decrease
The American College of Radiology (ACR) is encouraged by recent statistics and feels gratified that improved screening techniques and more effective treatment have contributed to the noticeable drop in national cancer mortality rates, according to a report published in the Annual Report to the Nation on the Status of Cancer.
“The ACR is proud of the research coordinated by our cooperative groups and by other institutions nationwide,” said Aril Van Moore, Jr., MD, chair of the ACR board of chancellors. “We are pleased that these types of research are leading to better diagnostic and radiation therapy techniques, which can help to improve disease detection, and save and extend lives.”
The ACR has conducted research in diagnostic imaging and radiation therapy for almost 40 years, through its clinical trials research groups, the ACR Imaging Network and the Radiation Therapy Oncology Group.
Recently, the ACR launched ACR Image Metrix, a contract research organization, which assists pharmaceutical and biotech manufacturers in anticancer drug development using cutting-edge imaging to assist in the more rapid assessment of new anticancer compounds.
“We are very encouraged by this recent report on the drop in cancer deaths and believe that the rapidly-expanding imaging technology and techniques for drug development will only continue to accelerate more anticancer drugs onto the market,” said Mike Morales, general manager for ACR Image Metrix.
“The ACR is proud of the research coordinated by our cooperative groups and by other institutions nationwide,” said Aril Van Moore, Jr., MD, chair of the ACR board of chancellors. “We are pleased that these types of research are leading to better diagnostic and radiation therapy techniques, which can help to improve disease detection, and save and extend lives.”
The ACR has conducted research in diagnostic imaging and radiation therapy for almost 40 years, through its clinical trials research groups, the ACR Imaging Network and the Radiation Therapy Oncology Group.
Recently, the ACR launched ACR Image Metrix, a contract research organization, which assists pharmaceutical and biotech manufacturers in anticancer drug development using cutting-edge imaging to assist in the more rapid assessment of new anticancer compounds.
“We are very encouraged by this recent report on the drop in cancer deaths and believe that the rapidly-expanding imaging technology and techniques for drug development will only continue to accelerate more anticancer drugs onto the market,” said Mike Morales, general manager for ACR Image Metrix.